Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Advisory Committee to Discuss 2 Lung Cancer Drugs on Feb. 26
February 16, 2016
- 3 Regenerative Medicine Products, 2 Medical Devices Designated for Sakigake Review: MHLW
February 15, 2016
- Chuikyo OKs Basic Plan for Pilot-Based HTA Scheme; Sovaldi, Opdivo Emerge as Likely Candidates
February 12, 2016
- Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
February 12, 2016
- Working Group Debate Kicks Off toward Realizing New Ryukaikon Proposal
February 12, 2016
- MHLW Sends Alert on Kids’ Accidental Ingestion of Psychotropics, Other Drugs
February 10, 2016
- Frequency of Drug Price Revisions to Be Discussed by Chuikyo: Govt
February 8, 2016
- MHLW Panel Supports Pain Indication for Cymbalta by Majority Vote
February 8, 2016
- Hep B Vaccines to Join Public Immunization Program in October
February 8, 2016
- Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
February 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for January
February 5, 2016
- MHLW Won’t Rule Out Single-Patient Humanitarian Trials: Official
February 5, 2016
- Council OKs Public Knowledge-Based Application for Capecitabine as Adjuvant Chemotherapy for Rectal Cancer
February 5, 2016
- Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation
February 4, 2016
- NCC, PMDA Forge Comprehensive Collaboration Pact
February 3, 2016
- MHLW Panel Backs Approval of Novartis’s Melanoma Drugs
February 2, 2016
- MHLW Allows Shipment of Kaketsuken’s Hep A, B Vaccines
February 2, 2016
- Chuikyo Reps Want Price-Based Penalty Added to Supplementary Opinions for FY2016 Reform Proposal, MHLW Expresses Caution
February 1, 2016
- Govt Says It’s “Not Recommending” Research-Driven Makers to Become Generic Makers, It’s One Option
February 1, 2016
- MHLW Sends Alert on Opdivo’s Fulminant Type 1 Diabetes Risk
February 1, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…